Abstract:Introduction: The study of the pathophysiology study of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. Methods: The humanized APP NL-G-F knock-in mouse line was crossed to the PS19 MAPT P301S , over-expression mouse line to create the dual APPNL-G-F/PS19 MAPTP301S line. The resulting pathologies were characterized by immunochemical methods and PCR. Results: We now report on a double transgenic APP NL-G-F /PS19 MAPT P301S mouse that at 6 months of age exhibits robust A plaque accumulation, intense MAPT pathology, strong inflammation and extensive neurodegeneration. The presence of A pathology potentiated the other major pathologies, including MAPT pathology, inflammation and neurodegeneration. MAPT pathology neither changed levels of amyloid precursor protein nor potentiated A accumulation. Interestingly, study of immunofluorescence in cleared brains indicates that microglial inflammation was generally stronger in the hippocampus, dentate gyrus and entorhinal cortex, which are regions with predominant MAPT pathology. The APP NL-G-F /MAPT P301S mouse model also showed strong accumulation of N 6 -methyladenosine (m 6 A), which was recently shown to be elevated in the AD brain. m 6 A primarily accumulated in neuronal soma, but also co-localized with a subset of astrocytes and microglia. The accumulation of m 6 A corresponded with increases in METTL3 and decreases in ALKBH5, which are enzymes that add or remove m6A from mRNA, respectively. Discussion: Our understanding of the pathophysiology of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. The APP NL-G-F /MAPT P301S mouse recapitulates many features of AD pathology beginning at 6 months of aging, and thus represents a useful new mouse model for the field. Graphical . This figure summarizes the pathophysiological changes occurring in the APP NL-G-F /MAPT P301S mouse model. This model has the humanized APP NL-G-F gene as a knocking. The neurons consequently produce abundant Aβ 40/42 which leads to rapid formation of extracellular Aβ plaques. The accumulation of Aβ stimulates inflammation and also feeds back to neurons to enhance MAPT pathology and neurodegeneration. The neurons over-express P301S MAPT, which leads to rapid formation of MAPT pathologies; the amount of pathology is enhanced modestly by the abundant production and aggregation of Aβ. The MAPT aggregation in the neurons stimulate the accumulation of cytoplasmic m 6 A, presumably as part of the translational stress response. Secreted MAPT stimulates microglial inflammation and astrocytosis. All of these factors accelerate neurodegeneration. The inflammation in this model tends to accumulate most in regions with MAPT pathology, particularly the hippocampus, although some reactive microglia are also observed near Aβ plaques.

Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice

Do Mouse Data Lie? for Buntanetap, They Totally Predict Human Outcome

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

Tau depletion in human neurons mitigates Aβ-driven toxicity

Deficiency of IKK in neurons ameliorates Alzheimer's disease pathology in APP- and tau-transgenic mice

P2-296: Enhanced Proteolysis of Aβ Peptide Reduces Tau Phosphorylation and Neurofibrillary Tangle Formation in APP/tau Transgenic Mice

Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

Decreased Hippocampal Cell Proliferation Correlates With Increased Expression Of Bmp4 In The Appswe/Ps1 Delta E9 Mouse Model Of Alzheimer'S Disease

APPsα rescues CDK5 and GSK3β dysregulation and restores normal spine density in Tau transgenic mice

The behavioural and neuropathologic sexual dimorphism and absence of MIP-3α in tau P301S mouse model of Alzheimer's disease

BMP4 Overexpression Induces the Upregulation of APP/Tau and Memory Deficits in Alzheimer’s Disease

Reduction of advanced tau‐mediated memory deficits by the MAP kinase p38γ

β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

The Behavioural And Neuropathologic Sexual Dimorphism And Absence Of Mip-3 Alpha In Tau P301s Mouse Model Of Alzheimer'S Disease

Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function.

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model

Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies